Literature DB >> 11805718

HIV drug interactions: the good, the bad, and the other.

Petrie M Rainey1.   

Abstract

Highly active antiretroviral therapy, involving treatment with three or four antiretroviral agents, has greatly improved the effectiveness of therapy for human immunodeficiency virus (HIV) infection. It has also extended the number of possible drug interactions that may occur in treated patients. There are 105 possible two-drug interactions among the 15 currently approved antiretroviral agents. Well-characterized interactions involving inhibition of drug metabolism have been exploited to reduce dose size or frequency and to simplify treatment regimens. Many additional interactions are possible with other drugs used to treat or prevent complications of HIV infection. Interactions with methadone and other opiate abuse therapies are also of concern. The usefulness of therapeutic drug monitoring for antiretroviral drugs remains controversial. However, drug measurements before introduction of an interacting drug can establish patient-specific targets that can guide subsequent dosing adjustment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11805718     DOI: 10.1097/00007691-200202000-00005

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  7 in total

Review 1.  Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?

Authors:  Karen Dahri; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 2.  [Clinical features, diagnosis and treatment of HIV-induced neuropsychiatric disorders].

Authors:  Hans-Bernd Rothenhäusler
Journal:  Wien Med Wochenschr       Date:  2006-12

Review 3.  Methadone: applied pharmacology and use as adjunctive treatment in chronic pain.

Authors:  R Brown; C Kraus; M Fleming; S Reddy
Journal:  Postgrad Med J       Date:  2004-11       Impact factor: 2.401

4.  Patterns and correlates of sexual activity and condom use behavior in persons 50-plus years of age living with HIV/AIDS.

Authors:  Travis I Lovejoy; Timothy G Heckman; Kathleen J Sikkema; Nathan B Hansen; Arlene Kochman; Julie A Suhr; John P Garske; Christopher J Johnson
Journal:  AIDS Behav       Date:  2008-04-04

5.  Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population.

Authors:  Carol Holtzman; Carl Armon; Ellen Tedaldi; Joan S Chmiel; Kate Buchacz; Kathleen Wood; John T Brooks
Journal:  J Gen Intern Med       Date:  2013-04-20       Impact factor: 5.128

6.  Moving toward personalized medicine in the methadone maintenance treatment program: a pilot study on the evaluation of treatment responses in Taiwan.

Authors:  Hsin-Ya Lee; Jih-Heng Li; Yuh-Ling Sheu; Hsin-Pei Tang; Wei-Chiao Chang; Tze-Chun Tang; Yi-Chun Yeh; Shing-Yaw Wang; Ray-H Liu
Journal:  Biomed Res Int       Date:  2013-12-16       Impact factor: 3.411

7.  Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy.

Authors:  Krista J Siefried; Limin Mao; Lucette A Cysique; John Rule; Michelle L Giles; Don E Smith; James McMahon; Tim R Read; Catriona Ooi; Ban K Tee; Mark Bloch; John de Wit; Andrew Carr
Journal:  AIDS       Date:  2018-01-02       Impact factor: 4.177

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.